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1. Introduction 
The prognosis of malignant solid tumors in children has been improved by 
multidisciplinary therapy involving surgery, radiotherapy and chemotherapy. High-dose 
chemotherapy (HDC) followed by autologous (Auto) or allogeneic (Allo) hematopoietic 
stem cell transplantation (HSCT) has contributed significantly to improvements in the 
prognosis of high-risk chemosensitive tumors. It has been utilized in many kinds of 
pediatric malignancies, not only hematopoietic tumors but also solid tumors such as 
neuroblastoma, brain tumors, Ewing’s sarcoma, osteosarcoma, Wilms’ tumor, 
rhabdomyosarcoma, hepatoblastoma, and retinoblastoma.  Fig, 1 shows the numbers of 
cases in which HSCT was used for pediatric solid tumors in Japan. When HSCT is utilized in 
patients with malignant solid tumors, there are several treatment objectives. First, it can be 
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conventional therapies. Second, it can be used in refractory or relapsed disease when 
conventional doses of anti-tumor drugs may have not reached or killed tumor cells. Third, it 
can be used for the immunological effect of Allo HSCT. Allo HSCT grafts sometimes have 
immunological anti-tumor effects called graft versus tumor (GVT) effects. Non-
myeloablative conditioning regimens with Allo HSCT for solid tumors are one such 
example. Furthermore, tandem HSCT to increase dose intensity and HSCT with targeted 
radionuclide therapy have been studied clinically. In this chapter, I review the literature on 
HSCT for malignant solid tumors, especially non-hematopoietic tumors in children 
according to tumor type and consider future therapy. 
Fig. 1. The Japan Society for Hematopoietic Cell Transplantation Office of Nationwide 
Survey, (March 2011), The Japan Society for Hematopoietic Cell Transplantation Annual Report of 
Nationwide Survey 2010, p. 60  
2. Neuroblastoma 
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. The 
prognostic indicators of NB are age at diagnosis, tumor stage as classified by the 
International NB Staging System (INSS) (Brodeur et al., 1993), amplification of the MYCN 
oncogene (Brodeur et al., 1984), and histological findings (Shimada et al., 1999). HSCT has 
been performed for high-risk NB, characterized as stage IV by INSS, stage III with other 
negative prognostic factors e.g. unfavorable histology (Shimada system), or any stage with 
amplification of the MYCN oncogene (Matthay et al., 1999; Weinstein et al., 2003). 
2.1 Stem cell sources for HSCT in NB 
Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) 
following mobilization by granulocyte colony-stimulating factor (G-CSF) are available for 
Auto HSCT in patients with NB (Fish & Grupp, 2008). Since NB cells infiltrate the bone 
marrow (BM) more frequently than peripheral blood (Cohn et al., 1997; Trager et al., 2003), 
and PB stem cells provide faster hematopoietic recovery, PB stem cells are used more often 
than BM cells in Auto HSCT (Fish & Grupp, 2008). Allo umbilical cord blood transplantation 
(CBT) from an unrelated donor, as well as Allo BMT or PBSCT, have also been performed in 
NB patients (Vanlemmens et al., 1992; Wagner, 1993). 
2.2 CD34+ positive selection of HSCT for NB 
Since minimal residual disease (MRD) in PBSC, as evaluated by anti-GD2 
immunofluorescence or tyrosine hydroxylase reverse transcriptase-polymerase chain 
reaction (RT-PCR), is one of the prognostic factors of NB, the positive selection of CD34+ 
Auto PB stem cells has been studied in NB (Marabelle et al., 2011). MRD has been shown to 
exist in the CD34 negative fraction with most NB cells removed by the selection. CD34+ 
positive selection does not affect long-term hematopoiesis although immune recovery is 
delayed. Treatment with 13-cis-retinoic acid therapy after HSCT is thought to be effective for 
MRD (Marabelle et al., 2011). 
2.3 Conditioning regimens of HSCT for NB 
As a preparative regimen prior to Auto or Allo HSCT for patients with NB, fractionated 
total body irradiation (TBI) or local irradiation is often utilized (Kushner et al., 1991). TBI-
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containing regimens to treat NB have acceptable toxicity and are as effective as non-TBI 
preparative regimens (Kamani et al., 1996; McCowage et al., 1995). Patients who receive TBI 
have long-term adverse effects such as growth failure (Hovi et al., 1999) and severe 
disturbances of dental development (Holtta et al., 2002) more often than patients who 
receive non-TBI-containing regimens. Many kinds of regimens, especially melphalan-based 
regimens with or without TBI, have been studied as conditioning regimens for Auto HSCT 
in high-risk NB patients (Yalcin et al., 2011). Recently, a study of 36 patients with high-risk 
NB (median age at transplantation: 3 years, range: 0.7–14 years) who received high-dose 
busulfan and melphalan as the conditioning regimen for Auto HSCT was reported. No toxic 
deaths were observed. With a median follow-up of 55 months, progression-free survival 
(PFS) was 57 ± 9% for the whole group and patients who achieved early complete remission 
(CR) following transplantation (3 months post-transplantation) had a better outcome than 
those who did not (PFS: 91 ± 6% vs. 9 ± 8%). They also showed younger patients with no 1p 
deletions had better outcomes (Molina et al., 2011). 
2.4 Randomized studies of HSCT for NB 
The Children’s Cancer Group (CCG) in the US first reported a randomized trial involving 
Auto HSCT.  High-risk NB patients between 1 to 18 years of age who received five cycles of 
initial chemotherapy (doxorubicin 30 mg/m2, etoposide 100 mg/m2 daily for 2 days, and 
cyclophosphamide 1000 mg/m2 daily for 2 days) who showed no disease progression were 
randomized to myeloablative therapy (carboplatin 1000 mg/m2, etoposide 640 mg/m2, 
melphalan 140 mg/m2), TBI (333 cGy daily for 3 days), or to three cycles of continuation 
chemotherapy (cisplatin 160 mg/m2, etoposide 500 mg/m2 and doxorubicin 40 mg/m2). The 
mean event-free survival (Fangusaro et al.) rate three years after randomization was 
significantly better among the 189 patients who were assigned to undergo transplantation 
than among the 190 patients assigned to receive conventional chemotherapy (34 ± 4% vs. 22 
± 4%, p = 0.034) (Matthay et al., 1999) . 
There are two reported randomized trials from Europe. The European NB Study Group 
(ENSG) demonstrated the value of melphalan myeloablative therapy. In their study, 167 
children with stage III or IV (44 stage III and stage IV from 6 to 12 month old at diagnosis, 
123 stage IV > 1 years old) were treated by initial induction chemotherapy consisting of 
vincristine, cisplatin, epipodophyllotoxin, and cyclophosphamide and surgical excision of 
the primary tumor. Ninety patients were achieved complete or good partial responses, and 
then 65 (72%) children were actually randomized either to high-dose melphalan (180 
mg/m2) with Auto bone marrow support or to no further treatment. The 5-year EFS with 
median follow-up from randomization of 14.3 years was 38% (95% confidence interval (CI): 
24–54%) in the melphalan-treated group and 27% (95% CI: 12–42%) in the group who did 
not receive melphalan. Although this difference was not statistically significant, the outcome 
of 48 randomized stage IV patients >1 year at diagnosis was significantly better in the 
melphalan-treated group (5-year EFS 33% vs. 17%, p = 0.01) (Pritchard et al., 2005). 
In Germany, a randomized study involving myeloablative HDC with Auto HSCT versus 
oral maintenance chemotherapy was conducted. Two hundred and ninety-five patients with 
high-risk NB (i.e. stage IV or MYCN amplified tumors) were randomly assigned to 
myeloablative HDC (melphalan, etoposide, and carboplatin) with Auto HSCT (n = 149) or 
oral maintenance chemotherapy with cyclophosphamide (n = 146). The 3-year EFS in the 
HDC group (47%, 95% CI: 38–55%) was better than that (30%, 95% CI: 45–62%) in the oral 
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maintenance therapy group (p = 0.0221), but there was no difference in overall survival (OS) 
(62%; 95% CI: 54–70% vs. 53%; 95% CI: 45–62%; p = 0.0875). In the HDC group, five patients 
died from acute complications related to HDC, but no patients on oral maintenance therapy 
died from acute treatment-related toxic effects (Berthold et al., 2005). 
2.5 MYCN Amplification in NB and HSCT 
In patients with stage II or III neuroblastoma with MYCN amplification, the prognosis of 
patients who received high-dose busulfan (600 mg/m2) and melphalan (140 mg/m2) (n = 12) 
is better than that of patients who received conventional chemotherapy (carboplatin, 
etoposide, vincristine, cyclophosphamide, and doxorubicin), radiotherapy, or both (n = 20). 
The 6-year OS was significantly different (25 ± 10% vs. 83 ± 11%; p = 0.004) (Laprie et al., 
2004). 
2.6 Tandem HSCT for NB 
Scheduled multiple cycles of (tandem) Auto HSCT for high-risk NB were reported first by 
Philip et al. They used two different regimens for advanced NB and harvested bone marrow 
twice before and after first BMT. The harvested bone marrow cells were purged in vitro by 
an immunomagnetic technique. The first regimen was a combination of tenoposid, 
carmustine, and cisplatinium (or carboplatin). The second regimen consisted of vincristine, 
melphalan, and TBI. This double HSCT achieved a prolonged relapse free survival (Philip et 
al., 1993). There are several reports of double Auto HSCT with one course of TBI (George et 
al., 2006; Sung et al., 2007) or without TBI (Grupp et al., 2000). Central nervous system 
relapse and secondary malignancies are rare in patients who receive tandem HSCT (George 
et al., 2006), although there is an increase in treatment-related deaths after the second HSCT 
(Grupp et al., 2000; Sung et al., 2007) and a higher rate of late adverse effects including 
growth hormone deficiency, dental problems, osteochondromas, and hearing deficiencies 
(Hobbie et al., 2008). Children’s Healthcare of Atlanta performed a study comparing single 
versus tandem HSCT for high-risk NB. There were 28 patients who received a single HSCT 
and 56 who received tandem HSCT. Tandem HSCT had a significantly improved 4-year EFS 
(59.3 ± 6.7% vs. 26.8 ± 9.2%, p = 0.01) and OS (70.6 ± 9.2% vs. 44.7 ± 11.2%, p = 0.06) when 
compared with single HSCT (Qayed et al., 2011). 
Triple-tandem HDC with PBSCT for high-risk NB was reported by two different groups. 
The conditioning regimens of the first first consisted of two courses of carboplatin (667 
mg/m2 daily for 2 days) and etoposide (1000 mg/m2 daily for 2 days) following one course 
of thiotepa (300 mg/m2 daily for 3 days) and cyclophosphamide (60 mg/kg daily for 3 
days). Seventeen patients were able to complete all three cycle of HSCT. The 3-year EFS and 
survival were 57 ± 11% and 79 ± 10%, respectively (Kletzel et al., 2002). The study by the 
Children’s Oncology Group in the US involved patients with stage IV NB receiving three 
cycles of interpatient dose escalating carboplatin (800 to 1000 mg/m2), cyclophosphamide (4 
g/m2) and etoposide (600 mg/m2). The overall 3-year EFS and OS rates were 20 ± 10% and 
26 ± 11%, respectively (Bensimhon et al., 2010). 
2.7 Allo HSCT for NB 
Allo HSCT with TBI for NB has been attempted more than a quarter century ago (August et 
al., 1984). Although the graft contains no contamination of tumor cells, initial studies of 
conventional Allo HSCT failed to show a clear clinical benefit with a high ratio of treatment-
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related mortality (TRM) and graft versus host diseases (GVHD) (Evans et al., 1994; 
Ladenstein et al., 1994; Matthay et al., 1994). However, the development of supportive care 
and the establishment of Allo HSCT for leukemia had renewed interest in Allo immunity for 
various malignant cells that is described as a graft versus tumor effect (GVT) (Pedrazzoli et 
al., 2002). Cytotoxic T-lymphocytes can target antigens found on malignant cells. These 
antigens include linage-restricted antigens found on tumors of similar origin and on related 
normal cells (e.g., GD2 ganglioside expressed in NB), antigens found on tumors of different 
origins but not on normal tissue, and tumor-specific antigens produced by mutant genes 
within the tumor (Navid et al., 2009).  
Clinical GVT was first described in a patient with NB who received HSCT from a HLA 
haplo-identical donor. Although the patient received further chemotherapy after the Allo 
HSCT and the response was not correlated to GVHD, the patient entered and sustained 
complete remission for 4 years (Inoue et al., 2003). A more recent report shows clinical GVT 
for NB is correlated with GVHD in a patient who underwent a reduced intensity Allo HSCT 
(Marabelle et al., 2007). In mice, efficient GVT for NB could be induced by donor 
lymphocyte infusion or immunomodulation with dendritic cells after Allo HSCT in the 
absence of GVHD (Ash et al., 2009; Ash et al., 2010). Allo CBT for NB was also performed 
since the early 1990s in three patients with advanced NB with highly amplified MYCN 
(Vanlemmens et al., 1992; Wagner, 1993). After receiving Auto HSCT followed by Allo CBT, 
they have maintained disease-free survival (DFS) for 37 to 60 months without severe acute 
complications (Goi et al., 2011). Recently, a reduced-intensity conditioning regimen 
(cyclophosphamide 50 mg/kg, fludarabine 40 mg/m2 daily for two days, TBI 200 cGy, and 
rabbit anti-thymocyte globulin 2.5 mg/kg daily for two days) followed by unrelated CBT 
was studied for patients with relapsed NB. Although all patients progressed after transplant 
(median: 55 days, range: 26 to 180 days), natural killer (NK) cell counts were normal within 
2 months with no evidence of GVHD, whereas the T-cell recovery was slower. These results 
show the possibility of treating patients with MRD after transplant with less intensive 
immunosuppression and adding NK-cell based post-transplant immunotherapy (Jubert et 
al., 2011). 
2.8 Radioactive Iodine therapy with HSCT for NB 
The norepinephrine analog metaiodobenzylguanidine (MIBG) is selectively accumulated in 
sympathetic nervous tissue, and several clinical studies of high dose iodine-131-labeled 
MIBG (131I-MIBG) in combination with myeloablative chemotherapy and Auto HSCT for the 
treatment of NB were performed. Although this regimen has acceptable toxicity (Yanik et 
al., 2002), six of 22 assessable patients had complete or partial remission and the 3-year EFS 
and survival rates were 31% ± 10% and 58% ± 10% (Yanik et al., 2002).  A case of 131I-MIBG 
therapy with reduced intensity Allo HSCT in recurrent extensive neuroblastoma was also 
reported. This patient achieved remission which was maintained for 3 months after 
transplantation (Takahashi et al., 2008). A study of high-dose 131I-MIBG with T cell-depleted 
haplo-identical HSCT and post-transplant immunotherapy in children with relapsed or 
refractory NB shows durable remission. All five patients in this study had no acute GVHD 
and four patients who received additional treatment with donor lymphocyte infusion (DLI) 
developed controllable chronic GVHD after DLI. Analysis of immunologic recovery showed 
a fast reappearance of NK- and T-cells. Two patients are alive with no evidence of disease 40 
and 42 months after transplantation (Toporski et al., 2009). A phase I trial in which patients 
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with refractory or relapsed NB received double 131I-MIBG infusions (target red marrow 
radiation index ranged from 22 to 50 mCi/kg) at 2-week intervals with Auto HSCT 2 weeks 
after the second dose was reported. This regimen had no dose-limiting toxicities and dose 
intensification of 131I-MIBG. The PFS at 6 and 12 months was 57 ± 11% and 33 ± 11%, 
respectively (Matthay et al., 2009).  
3. Brain tumors 
Brain tumors are the most common pediatric malignant tumors with various types and 
various grades of malignancy. Recent advances in multidisciplinary treatment have 
improved the OS of pediatric brain tumors, especially chemotherapy-sensitive high-grade 
malignant tumors such as medulloblastoma (MB) or primitive neuroectodermal tumors 
(PNET). Many studies of HSCT were undertaken for high-grade pediatric brain tumors that 
are both chemotherapy-sensitive and resistant. Initial HSCT studies for high-grade glioma 
and ependymoma, which are relatively chemotherapy-resistant, failed to show an efficient 
clinical effect (Grill et al., 1996; Kalifa et al., 1992), although HSCT for patients with high-risk 
MB played an important role in improving survival (Gajjar & Pizer, 2010). Recently, 
molecular targeted therapies for adult high-grade gliomas and various grades of pediatric 
glioma or ependymoma are being studied (Tsuruta et al., 2011a). The combination of 
molecular therapy and HSCT may be of special interest in such chemotherapy-resistant 
cases. 
3.1 Conditioning regimens & stem cell sources of HSCT for brain tumors 
Until the early 1990's, high-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) based 
regimens followed by Auto BMT were utilized for high-risk brain tumors, especially for 
high-grade glioma in adults. In 1979, the first use of intensive BCNU and Auto BMT for 
brain tumors was reported with doses of 900 mg/m2 and 1500 mg/m2 (Phillips et al., 1979). 
Subsequent reports of single treatment BCNU showed the limiting dose of BCNU ranges 
from 600 to 1,200 mg/m2 (Hochberg et al., 1981; Phillips et al., 1983). Although several 
studies of high-dose BCNU treatment for high-grade glioma showed responses (Hochberg 
et al., 1981) or prolonged survival when compared with historical control groups (Johnson et 
al., 1987), the effects were thought to be limited by late toxicity (Phillips et al., 1986).  In 
France, an analysis of high-dose BCNU (800 mg/m2) single treatment followed by Auto 
HSCT (BMT = 84, PBSCT = 30) and local irradiation (60 Gy) for patients (median age, 44 
years) with supratentorial high-grade glioma (glioblastoma (GB) = 78, anaplastic 
astrocytoma (AA) = 24, anaplastic oligodendroglioma (OD) = 12) was performed. With 89 
months of median follow-up, the OS was 12 months for GB, 37 months for OD, and 81 
months for AA. There were some long-term survivors, although OS was comparable to that 
described for other treatments (Durando et al., 2003). A BCNU combination regimen (BCNU 
600 mg/m2, thiotepa 900 mg/m2, and etoposide 1,500 or 750 mg/m2) followed by BMT and 
local irradiation was studied in 42 relatively young patients (median age, 12.2 years) with 
high-risk brain tumors at 10 academic oncology centers in the US, UK, and Australia. Of 25 
(GB = 20) evaluable newly diagnosed patients, 20% achieved CR and 4% partial remission 
(PR), while 28% remained in continuing complete remission (CCR) and 44% remained with 
stable disease prior to radiation therapy Of eight (GB = 3) evaluable patients with recurrent 
disease, one (GB = 1) achieved CR and two (GB = 1) PR, while one (GB = 1) remained in 
CCR and four with stable disease for 1 to 110.2 months (Papadakis et al., 2000).  
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A Phase II study of high-dose busulfan (150 mg/m2 daily for 4 days) and thiotepa (350 
mg/m2 daily for 3 days) followed by BMT in children with recurrent brain tumors was 
designed in France.  In 20 children (median age, 6 years), five partial responses (3/6 MB, 1/5 
ependymoma, 1/2 PNET), three objective responses, ten cases of stable disease, and one 
case of progressive disease were observed, although one patient died due to toxicity. There 
were high levels of toxicity in terms of aphasia and cutaneous, hepatic, and neurological 
complications (Kalifa et al., 1992). Subsequent studies of regimens of thiotepa + etoposide, 
cyclophosphamide + melphalan, busulfan + melphalan, carboplatin + etoposide, and 
thiotepa + melphalan followed by BMT (or PBSCT) in patients with high-risk brain tumors 
reported some long-term survivors, including some patients with recurrent tumors (Finlay 
et al., 1996; Graham et al., 1997; Hara et al., 1998; Mahoney et al., 1996). In patients with 
recurrent tumors, long-term survivors usually have local recurrence, and patients with 
disseminated tumors have very poor prognosis (Graham et al., 1997)  
Recently, a study of low-dose continuous intravenous etoposide (day −22 to day −2) along 
with high-dose carboplatin (667 mg/m2 daily or area under the curve (AUC) = 9 
mg/ml/min for 3 days) and thiotepa (300 mg/m2 daily for 3 days) followed by HSCT 
conducted in patients with recurrent malignant brain tumors reported that some patients 
had long-term survival (Grodman et al., 2009). 
3.2 HSCT & type of brain tumors 
HSCT was often considered in patients with high-risk (e.g. metastatic or disseminated) or 
recurrent MB. The Children’s Cancer Group in the US reported 23 patients with recurrent 
MB who were treated with Auto HSCT and a conditioning regimen consisting of 
carboplatin, thiotepa, and etoposide. This resulted in long-term survivors; the EFS and OS 
were 34 ± 10% and 46 ± 11%, respectively, at 36 months post-HSCT (Dunkel et al., 1998). In 
Spain, 19 patients with high-risk (n = 13) and recurrent (n = 6) MB and supratentorial PNET 
were treated with high-dose busulfan and melphalan followed by Auto HSCT. The 2-year 
EFS was 38 ± 14% in all patients and 57 ± 15% for the high-risk group (Perez-Martinez et al., 
2005).  In France, high-dose busulfan and thiotepa with HSCT followed by posterior fossa 
irradiation for local MB recurrence or progression after conventional chemotherapy was 
studied in 39 children (median age at diagnosis, 31 months) and was showed to yield a high 
OS rate (68.8% at 5 years; 95% CI: 53.0–81.2%) (Ridola et al., 2007).  A risk-adapted 
craniospinal radiotherapy (23.4–39.6 Gy) followed by high-dose HSCT (St Jude 
Medulloblastoma-96) performed at St. Jude Children’s Research Hospital also showed an 
improved outcome (Gajjar et al., 2006). Patients aged < 3 years at diagnosis had a better 
outcome (Shih et al., 2008). Pre-relapse definitive radiation therapy is thought to be one of 
the prognostic factors for recurrent MB. HDC is not effective in patients with recurrent MB 
who received cranial radiation therapy prior to recurrence (Gururangan et al., 2008; 
Massimino et al., 2009). 
In the 1990s, two studies of HDC (thiotepa, busulfan, etoposide, and carboplatin) followed 
by HSCT for patients with recurrent ependymoma failed to show clinical efficacy (Grill et 
al., 1996; Mason et al., 1998). On the other hand, for patients with relapsed or progressive 
central nervous system germ cell tumors, thiotepa-based HDC regimens followed by HSCT 
were studied. Patients with germinomas have better outcomes than patients with 
nongerminomatous germ cell tumors (Modak et al., 2004).  
Central nervous system atypical teratoid/rhabdoid tumors (CNS AT/RT) are rare tumors of 
childhood with a very poor prognosis. Median survival of CNS AT/RT is less than 1 year 
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with conventional therapy. One study involving high-dose carboplatin, thiotepa, and 
etoposide followed by HSCT was performed in 13 patients with CNS AT/RT after tumor 
resection and conventional chemotherapy consisting of cisplatin, vincristine, 
cyclophosphamide, and etoposide with or without high-dose methotrexate. Three of seven 
patients who received the high-dose methotrexate combined HSCT regimen had long-term 
remission (42+, 54+, and 67+ months), although they received no radiation therapy (Gardner 
et al., 2008). Trilateral retinoblastoma is also a rare brain tumor in the pineal region with 
very poor prognosis. HDC for trilateral retinoblastoma has some effect (De Ioris et al., 2010; 
Dunkel et al., 2010b), even if the tumor has relapsed (Tsuruta et al., 2011b). 
3.3 HSCT for young children with brain tumors 
HSCT is often considered for young children with newly diagnosed MB instead of radiation 
therapy because cranial irradiation in young children is thought to incur late complications 
(Kim et al., 2010).  In the US, the Memorial Sloan-Kettering Cancer Center study of HDC 
followed by Auto BMT for young children with newly diagnosed malignant brain tumors 
shortened the period of maintenance chemotherapy and reduced the risk of radiation 
therapy and had some long survivors (Mason et al., 1998). The neuropsychological findings 
of patients who received BMT revealed within low average range of intelligence (Sands et 
al., 1998). They also studied Auto BMT for young children with recurrent malignant tumors 
and showed that HDC with BMT followed by additional external-beam irradiation is 
effective for some young children with recurrent malignant tumors (Guruangan et al., 1998).  
Patients with supratentorial PNET have poor outcomes when compared to MB. HDC 
followed by HSCT in young patients with newly diagnosed supratentorial PNET provides 
improved EFS and OS and radiation therapy for these patients can sometimes be deferred or 
eliminated (Fangusaro et al., 2008). 
3.4 Tandem & allo HSCT for brain tumors 
Tandem HSCT is performed for brain tumors as well as neuroblastoma.  Two courses of 
high-dose melphalan (100 mg/m2) with PBSCT in 16 patients with cerebral PNET safely 
resulted in a high response rate, i.e. 11 PR in 14 patients with measurable disease (Vassal et 
al., 2001). A study of children with newly diagnosed MB and supratentorial PNET who were 
treated with four cycles of high-dose cyclophosphamide (4,000 mg/m2), cisplatin (75 
mg/m2), and vincristine (1.5 mg/m2 x 2) with 49 of 53 patients completing all four cycles 
and HSCT showed a 2-year PFS rate of 73.7 ± 10.5% for high-risk patients (residual tumor ≥ 
1.5 cm2 after conventional therapy) and 93.6 ± 4.7% for average-risk patients (Strother et al., 
2001). In Korea, 18 patients with high-risk solid tumors including brain tumors received two 
courses of HDC (cyclophosphamide, melphalan, thiotepa, carboplatin, etoposide, etc.) with 
HSCT. In this study, all patients with MB were alive and disease-free, although patients 
with other types of brain tumors died (Sung et al., 2003). Our case report series showed that 
double HDC consisting of melphalan and thiotepa may cure patients with primary 
disseminated MB; however, a patient with high expression of erythroblastic leukemia viral 
oncogene homolog 2 (ERBB2) relapsed (Aihara et al., 2010).  Recently, there is a report that 
single HSCT regimens have greater toxicity than ≥ 3 tandem HSCT which use milder HDC 
per HSCT cycle (Panosyan et al., 2011). 
Allo HSCT for brain tumors is still experimental, although there are case reports from 1992 
(Lundberg et al., 1992; Tsuruta et al., 2011b). An antitumor GVT effect associated with 
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chronic GVHD was observed in a patient with metastatic MB after Allo HSCT, (Secondino et 
al., 2008). 
4. Ewing’s sarcoma 
Studies of Auto BMT for patients with Ewing’s sarcoma (ES) were reported in both adults 
and children since the early 1980s. In initial studies of Auto BMT for ESwing, melphalan-
based conditioning regimens were used for disseminated or relapsed patients, with some 
achieving remission (Cornbleet et al., 1981; Graham-Pole et al., 1984). Subsequent studies of 
Auto HSCT for ES involved regimens combined with TBI or busulfan. 
4.1 TBI combined regimens for ES 
Until the 1990s, TBI-combined regimens were often utilized.  Regimens consisting of TBI (12 
Gy), melphalan, and etoposide with or without carboplatin for multi-focal or relapsed ES 
showed better outcomes (relapse-free survival 45 ± 12% at 6 years) when compared with 
historical controls (Burdach et al., 1993). For patients with high-risk ES in first CR, HSCT 
with or without TBI was associated with a DFS of 62.7 ± 11% overall and 40 ± 21.9% for 
those with metastatic disease (Madero et al., 1998).  One study of HSCT with versus without 
TBI for patients with primary metastatic (stage IV) ES (n = 171) showed improved prognosis 
(overall EFS 40% vs. 19%), although patients with pulmonary or skeletal metastases had 
especially poor outcome (EFS 27% vs. 0%) (Paulussen et al., 1998). HSCT with TBI for 
patients with ES did not improve the prognosis of patients with metastases to bone or bone 
marrow; the majority experienced relapse and died with progressive disease (Kushner & 
Meyers, 2001; Meyers et al., 2001). Recurrent ES also has a poor prognosis. However, in 
secondary remission HSCT can improve the prognosis of recurrent ES (Barker et al., 2005). 
4.2 Busulfan & melphalan regimens for ES 
Since the late 1990s busulfan has been often utilized instead of TBI. Studies of melphalan-
based conditioning regimens including busulfan were reported from several groups. In 21 
children with high-risk ES resistant to conventional therapy and recurrent disease, PBSCT 
with melphalan-based regimens did not show any benefit (Drabko et al., 2005). In a study of 
33 recurrent or progressive ES patients treated with regimens of high-dose busulfan or 
melphalan with or without TBI, some patients achieved long-term survival although the 
treatment was associated severe toxicity (McTiernan et al., 2006). In 2006, in Europe the 
benefits of high-dose busulfan (600 mg/m2) and melphalan (140 mg/m2) for ES with 
metastasis to lung or bone without bone marrow involvement were shown (Oberlin et al., 
2006). The subsequent Euro-EWING-99 trial reported an estimated 3-year EFS of 45% in 46 
children younger than 14 years with primary disseminated multifocal ES (Ladenstein et al., 
2010). Recently, an Italian and Scandinavian group showed the effectiveness of HSCT with 
busulfan and melphalan for patients with non-metastatic, poor-response ES (5-year EFS of 
HSCT and non-HSCT group was 72% and 33%) (Ferrari et al., 2011). 
4.3 Tandem HSCT for ES 
The European Intergroup Cooperative Ewing Sarcoma Study (EICESS) compared the 
regimen of HyperME (TBI 12 Gy,  melphalan 120 to 180 mg/m2, etoposide 40 to 60 mg/kg, 
and carboplatin maximum dose 1,800mg) to TandemME (two cycles of melphalan 120 to 
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140mg/m2 and etoposide 60mg/kg).  The 5-year EFS of Hyper ME and TandemME were 22 
± 8% and 29 ± 9%, respectively, while the lethal complication rate was 23% in HyperME and 
4% in TandemME (Burdach et al., 2003). A study using two cycles of alkylating agent-based 
HDC for primary metastatic bulky disease or recurrent ES showed acceptable toxicities and 
OS of 45% and EFS of 47% at 3 years, although only 65% of patients were able to proceed to 
the second cycle (Rosenthal et al., 2008).  
4.4 Allo HSCT for ES 
From EICESS, 26 cases of Auto HSCT and 10 cases of Allo HSCT for multifocal or recurrent 
advanced ES were reported. Although patients who received Allo HSCT failed to show 
allogeneic immunological effects e.g. GVT, eight of 26 cases with Auto HSCT received 
systemic interleukin-2 (IL-2) therapy after HSCT. The IL-2 group had a better EFS rate (60 ± 
18%) compared to the groups that received Allo HSCT (20 ± 13%) alone or Auto HSCT alone 
(22 ± 13%) (Burdach et al., 2000).  A case report of a 6 year-old girl with multifocal ES who 
received Allo HSCT from her HLA-matched mother showed a shrinkage of her pulmonary 
tumors and grade 1 GVHD during a taper of the immunosuppression (Lucas et al., 2008). 
Recently, reduced- versus high-intensity conditioning for Allo HSCT was compared. There 
was no improvement in survival with reduced intensity conditioning due to an increased 
rate of death caused by  disease and relapse (Thiel et al., 2011). 
5. Osteosarcoma 
The prognosis of metastatic or relapsed osteosarcoma is very poor. High-dose methotrexate 
has been used since the 1970s, but HSCT for osteosarcoma remains experimental. There are 
fewer reports of HSCT for osteosarcoma than for ES since patients with metastatic or 
recurrent disease have < 20% chance of long-term survival despite aggressive treatment 
(Chou et al., 2008). However, many kinds of new agents including antifolate compounds 
and muramyl tripeptide phosphatidylethanolamine are under investigation (Jaffe, 2009). 
The initial study of HSCT in two cases of advanced osteosarcoma failed to reveal a clinical 
effect. In 2001, the Cooperative German-Austrian-Swiss Osteosarcoma Study Group 
reported the results of HSCT in 15 patients with relapsed osteosarcoma. Three of the 15 
patients died of toxic complications and the treatment outcome was not better than with 
conventional therapy (Sauerbrey et al., 2001). A study using tandem HSCT for relapsed 
osteosarcoma by the Italian Sarcoma Group Study showed two points: only patients who are 
chemosensitive to induction treatment can obtain complete remission after HSCT, and the 
length of remission is short (Fagioli et al., 2002).  From Japan, two case reports of Allo HSCT 
for osteosarcoma were presented.  In the first case, non-myeloablative chemotherapy 
followed by PBSCT for a third CR showed a GVT effect in reduction of the metastatic lung 
lesion with GVHD (Kounami et al., 2005). In the second report, a patient with progressive 
osteosarcoma and multiple lung and bone metastases received TBI combined with 
myeloablative HCT (thiotepa 600 mg/m2 and etoposide 1,000mg/m2) followed by Allo 
BMT. The metastatic lesions successfully disappeared (Goi et al., 2006). 
6. Wilms’ tumor 
Although multidisciplinary therapies including chemotherapy improved the cure rate of 
Wilms’ tumor (WT) to approximately 80–85%, the EFS in recurrent disease was less than 
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15% before HDC with HSCT was developed (Grundy et al., 1989). Furthermore, a number of 
adverse prognostic factors related to poor outcomes during relapse have been identified and 
are used as inclusion criteria for studies involving HSCT (Dallorso et al., 2008) e.g. loss of 
heterozygosity in chromosomes 1p and 16q (Grundy et al., 2005). 
The European Bone Marrow Transplantation for Solid Tumor Registry reported a study of 
25 children with WT (12 stage IV, 5 stage III, 3 stage II, and 1 stage I) who were treated with 
Auto BMT and melphalan-based or other regimens. Of 21 recurrent cases, 13 achieved 
second or subsequent CR after Auto BMT and eight patients were event-free at 14–90 
months (Garaventa et al., 1994). High-dose melphalan, etoposide, and carboplatin (MEC) 
followed by Auto HSCT in high-risk recurrent WT patients with chemotherapy-responsive 
disease was evaluated prospectively by the French Society of Pediatric Oncology. The  DFS 
and OS at 3 years were 50 ± 17% and 60 ± 18%, respectively (Pein et al., 1998). A report of 23 
patients with high-risk WT, including 20 recurrent cases, treated with HDC including MEC 
followed by Auto HSCT in the German Cooperative Wilms Tumor Studies showed an 
estimated survival and EFS are 60.9% and 48.2% (Kremens et al., 2002).  At the Children’s 
Memorial Hospital in Chicago, one or two cycles of HSCT were tried in patients with 
relapsed WT. The EFS and OS of this study at 4 years were 60% and 73%, respectively 
(Campbell et al., 2004). A study in Italy also showed the benefit of Auto HSCT for high-risk 
relapsed WT with a 3-year DFS approaching 50% (Spreafico et al., 2008).  A meta-analysis of 
6 studies with or without HDC followed by Auto HSCT revealed that patients who only 
relapsed in the lung have a higher survival rate than those who relapsed in other locations. 
The 4-year survival rate among stage I or II patients was about 30% higher in the no HSCT 
group than the HSCT group, but the 4-year survival rate was similar in HSCT vs. no-HSCT 
in stage III and IV patients. These findings suggest that salvage chemotherapy is typically 
the better choice for relapsed WT patients, and that HSCT could be considered for stage III 
or IV patients with relapse only in the lungs (Presson et al., 2010). There is a case report 
describing a refractory case of WT with lung metastasis being cured by CBT (Massimino et 
al., 2010). There are rare case reports of WT successfully treated by HSCT, e.g. a case of third 
remission (Brown et al., 2010), a bilateral Wilms’ tumor treated without any irradiation 
(Saarinen-Pihkala et al., 1998), and an anephric pediatric case with multiple recurrent WT 
treated in conjunction with hemodialysis (Dagher et al., 1998). 
7. Rhabdomyosarcoma 
Since the end of 1990s, the prognosis of patients with localized rhabdomyosarcoma (RS) has 
improved with an EFS rate of approximately 70%. Although HDC with or without TBI 
followed by Auto or Allo HSCT has been performed for patients with metastatic or 
recurrent diseases by several groups, a retrospective multi-center analysis with 36 patients 
by the German and Austrian Pediatric Bone Marrow Transplantation Group in 1997 showed 
that the effect of HSCT was uncertain. In this study, the EFS rate at 2 years after HDC in 26 
patients who were treated with MEC with or without TBI regimen was 36 ± 7%, and none of 
the 5 patients who received Allo BMT alive (Koscielniak et al., 1997). The European 
Intergroup MMT4-89 (including 4 cycles of standard chemotherapy) and MMT4-91 
(melphalan-based HDC followed by HSCT after three courses of standard chemotherapy) 
studies on childhood metastatic RS suggested that there was prolonged survival with the 
MMT4-91 regimen (EFS and OS at 3 years were 29.7% and 40%, respectively) when 
compared with the MMT4-89 regimen (EFS and OS at 3 year were 19.2% and 27.7%, 
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respectively) (Carli et al., 1999).  However, their final report concluded there is no evidence 
that consolidation HDC improves outcomes (Carli et al., 2004).  The analysis of 177 patients 
with stage IV RS from 22 studies who received HSCT also concluded that HSCT for patients 
with relapsed or refractory high-risk RS does not provide a significant advantage (Weigel et 
al., 2001). A recent meta-analysis of three non-randomized controlled studies on survival 
showed 3-year OS ranged from 22% to 55% in the HSCT group versus 18% to 55% in the 
control group, and also showed no differences between treatments (Peinemann et al., 2011). 
On the other hand, an analysis of HSCT for high-risk RS according to histological type 
suggested that for unfavorable histologies (alveolar or undifferentiated subtypes) HSCT 
after relapse may have some benefit because long-term survivors were sometimes seen (Stiff 
et al., 2010). 
8. Hepatoblastoma 
HCT followed by Auto or Allo HSCT for patients with high-risk hepatoblastoma (HB) was 
tried by several groups. The initial report described three patients with stage II or III HB 
who achieved CR after receiving Auto HSCT, and one patient with a third relapse showed 
PR (Hara et al., 1998). HSCT for MRD may improve survival (Yoshinari et al., 1998).  
Subsequent reports of tandem HSCT for three high-risk patients (metastatic or recurrent 
disease) showed that they failed to remain in remission (Katzenstein et al., 2002). Recent 
reports by the Japanese Study Group for Pediatric Liver Tumors also showed that the 
prognosis of HDC with HSCT for metastatic HB was poor (5-year OS of 43.9%) (Hishiki et 
al., 2011). On the other hand, a report of a patient with recurrent metastatic HB who 
received non-myeloablative HSCT from a HLA-matched unrelated donor showed a 
probable GVT effect with GVHD (Inaba et al., 2006). 
9. Retinoblastoma 
The prognosis of retinoblastoma improved to a 5-year survival rate of approximately 90% 
through early diagnosis and proper treatment, including enucleation, chemotherapy, or 
radiation therapy.  However, the outcome of progressive disease, i.e. optic nerve invasion, 
extra-ocular extension, or metastatic disease, especially into central nervous system (CNS), 
remains poor (Ali et al., 2011; Chantada et al., 2007; Cozza et al., 2009).  Since the 1980s, 
HDC with HSCT with or without TBI has been performed with immunomagnetic purging 
(Saleh et al., 1988), or monitoring of MRD in the BM or PB by monoclonal antibody of 3A7 
(Saarinen et al., 1991) or protein gene product 9.5 gene expression (Yamane et al., 1999) 
because retinoblastoma frequently infiltrates into these sites  (Karcioglu et al., 1997). Several 
trials of Auto HSCT for metastatic retinoblastoma with or without CNS involvement were 
reported.  Patients without CNS involvement were successfully treated by HDC followed by 
HSCT with or without local irradiation (Dunkel et al., 2000; Kremens et al., 2003; Matsubara 
et al., 2005). A patient with recurrent disseminated retinoblastoma in the lymph nodes, 
bone, and BM was successfully treated by HDC with CD34-selected Auto HSCT (Hertzberg 
et al., 2001). High-dose carboplatin (250 or 350 mg/m2 daily for 5 days), etoposide (350 
mg/m2 daily for 5 days), and cyclophosphamide (1.6 g/m2 daily for 4 days), followed by 
HSCT, can improve survival in retinoblastoma involving bone or BM but not the CNS 
(Namouni et al., 1997). A patient with cerebrospinal fluid metastasis who received HSCT 
with high-dose/short-infusion cyclosporine to inhibit P-glycoprotein, which is expressed by 
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most metastatic retinoblastomas, achieved long-term remission (Dimaras et al., 2009). A 
recent study of HDC with Auto HSCT for stage 4b (CNS involvement) retinoblastoma 
showed some benefit for some patients with CNS metastasis (Dunkel et al., 2010a).  
Furthermore, a study of HDCT in South America for metastatic retinoblastoma with CNS 
involvement also showed that 2 of 4 patients with CNS involvement were alive and disease 
free at 39 and 27 months (Dunkel et al., 2010a). Tandem HSCT was attempted to treat 
advanced bilateral retinoblastoma. Nine patients with bilateral retinoblastoma received two 
cycles of HDC with regimens of MEC + BM (busulfan and melphalan) or CTE (carboplatin, 
thiotepa, and etoposide) + CM (cyclophosphamide and melphalan) followed by Auto HSCT 
in order to avoid external-beam radiation therapy. All patients had at least one functional 
eye and in two patients both eyes were preserved (Lee et al., 2008).  
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